Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	WEINBERGEROVÁ Barbora MAYER Jiří KABUT Tomas SPERR Wolfgang R STEVKOVA Jana JONASOVA Anna CERNAN Martin HERNDLHOFER Susanne ORAVCOVA Iveta SRAMEK Jiri NOVAK Jan ŠTĚPÁNOVÁ Radka SZOTKOWSKI Tomas DRGONA Lubos ZAK Pavel VALENT Peter
Year of publication	2024
Type	Article in Periodical
Magazine / Source	British journal of haematology
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://onlinelibrary.wiley.com/doi/10.1111/bjh.19670
Doi	http://dx.doi.org/10.1111/bjh.19670
Keywords	acute myeloid leukaemia; antifungal prophylaxis; fungal infection; venetoclax and azacitidine
Attached files	Fungal_infection_frequency_in_newly_diagnosed_acute_myeloidleukaemia_patients_treated_with_venetoclax_plus_azacitidine_with_orwithout_antifungal_prophylaxis.pdf
Description	Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.
Related projects:	National institute for cancer research